1. Bohan A, Peter J Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344–347 (1975).
2. Bohan A, Peter J Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292: 403–407 (1975).
3. Allenbach Y, Benveniste O, Goebel HH, Stenzel W Integrated classification of inflammatory myopathies. Neuropathol Appl Neurobiol 43: 62–81 (2017).
4. Nakashima R, Hosono Y, Mimori T Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus 25: 925–933 (2016).
5. Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, Usui T, Tanaka M, Nagai S, Umehara H, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 39: 233–241 (2006).
6. Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clin Rev Allergy Immunol 52: 1–19 (2017).
7. Nakashima R, Mimori T Clinical and pathophysiological significance of myositis-specific and myositis- associated autoantibodies. Int J Clin Rheumatol 5: 523–536 (2010).
8. Palterer B, Vitiello G, Carraresi A, Giudizi MG, Cammelli D, Parronchi P Bench to bedside review of myositis autoantibodies. Clin Mol Allergy 16: 1–17 (2018).
9. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovsky J, De Visser M, Hughes RA 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14: 377–345 (2004).
10. De Bleecker JL, De Paepe B, Aronica E, de Visser M, Amato A, Benveniste O, De Bleecker J, De Boer O, Dimachkie M, Gherardi R, et al. 205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies Part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord 25: 268–272 (2015).
11. Lundberg IE, Tj A, Bottai M, Werth VP, Pilkington C, Visser M De, Alfredsson L, Amato AA, Barohn RJ, Liang MH, et al. 2017 European League Against Rheumatism / American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheum 69: 2271–2282 (2017).
12. Maeda MH, Tsuji S, Shimizu J Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain 135: 1767–1777 (2012).
13. Albrecht I, Wick C, Hallgren A, Tjärnlund A, Nagaraju K, Andrade F, Thompson K, Coley W, Phadke A, Diaz-Gallo LM, et al. Development of autoantibodies against musclespecific FHL1 in severe inflammatory myopathies. J Clin Invest 125: 4612–4624 (2015).
14. Gilhus NE Myasthenia gravis. N Engl J Med 375: 2570–2581 (2016).
15. Behan WMH, Behan PO, Doyle D Association of myasthenia gravis and polymyositis with neoplasia, infection and autoimmune disorders. Acta Neuropathol 57: 221–229 (1982).
16. van de Warrenburg B, Hengstman G, Vos P, Boerman R, ter Laak H, van Engelen B Concomitant dermatomyositis and myasthenia gravis presenting with respiratory insufficiency. Muscle Nerve 25: 293–296 (2002).
17. Ago T, Nakamura M, Iwata I, Murai H, Okuma K, Tsuru T, Kaji Y, Hayashida K, Niho Y Dermatomyositis Associated with Invasive Thymoma. Intern Med 38: 155–159 (1999).
18. Hassel B, Ne G, Ja A, Or S Fulminant myasthenia gravis and polymyositis after thymectomy for thymoma. Acta Neurol Scand 85: 63–65 (1992).
19. Seton M, Wu CC, Louissaint A Case 26-2013 : A 46-year-old woman with muscle pain and swelling. N Engl J Med 369: 764–773 (2013).
20. Shah A, Pace A, Hilton D, Househam E, Weatherby S Giant cell myositis responsive to combined corticosteroids and immunoglobulin. Pr Neurol 15: 456–459 (2015).
21. Hausmanowa-Petrusewicz I, Blaszczyk M, Jablońska S Coexistence of scleromyositis associated with PM-SCL antibody and myasthenia. Neuromuscul Disord 5: 145–147 (1995).
22. Ko KF, Ho T Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma. J Neurol Neurosurg Psychiatry 59: 558–559 (1995).
23. Saeki S, Fukusako T, Negoro K, Nogaki H, Morimatsu M, A Polymyositis Followed by Myasthenia Gravis. Jpn J Geriat 33: 532–534 (1996).
24. Kornizky Y, Heller I, Isakov A, Shapira I, Topilsky M Dysphagia with Multiple Autoimmune Disease. Clin Rheumatol 19: 321–323 (2000).
25. Shimojima Y, Gono T, Yamamoto K, Hoshi K, Matsuda M, Yoshida K, Ikeda SI Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. Clin Rheumatol 23: 262–265 (2004).
26. Shichijo K, Mitsui T, Kunishige M, Kuroda Y, Masuda K, Matsumoto T Involvement of mitochondria in myasthenia gravis complicated with dermatomyositis and rheumatoid arthritis: A case report. Acta Neuropathol 109: 539–542 (2005).
27. Venna N, Gonzalez RG, Zukerberg LR Case 39-2011: A woman in her 90s with unilateral ptosis. N Engl J Med 365: 2413–2422 (2011).
28. Avni I, Sharabi Y, Sadeh M, S.Buchman A Eosinophilia, myositis, and myasthenia gravis associated with a thymoma. Muscle Nerve 34: 242–245 (2006).
29. Zamecnik J, Vesely D, Jakubicka B, Simkova L, Pitha J, Schutzner J, Mazanec R, Vogel H Muscle lymphocytic infiltrates in thymoma-associated myasthenia gravis are phenotypically different from those in polymyositis. Neuromuscul Disord 17: 935–942 (2007).
30. Kidher ES, Briceno N, Taghi A, Chukwuemeka A An interesting collection of paraneoplastic syndromes in a patient with a malignant thymoma. BMJ Case Rep 10: 1136 (2012).
31. Paik JJ, Corse AM, Mammen AL The co-existence of myasthenia gravis in patients with myositis: A case series. Semin Arthritis Rheum 43: 792–796 (2014).
32. Lin J, Lu J, Chongbo Z, Kai Q, Wenhua Z, Dongyue Y, Sushan L, Yin W, Wentao F, Jiahong L Giant cell polymyositis associated with myasthenia gravis and thymoma. J Clin Neurosci 21: 2252–2254 (2014).
33. Stefanou MI, Komorowski L, Kade S, Bornemann A, Ziemann U, Synofzik M A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis. BMC Neurol 16: 1–4 (2016).
34. Inoue M, Kojima Y, Shinde A, Satoi H, Makino F, Kanda M SH Concurrence of myasthenia gravis, polymyositis, thyroiditis and eosinophilia in a patient with type B1 thymoma. Rinsho Shinkeigaku 47: 423–428 (2007).
35. Santos E, Coutinho E, Martins da Silva A, Marinho A, Vasconcelos C, Taipa R, Pires MM, Gonçalves G, Lopes C, Leite MI Inflammatory myopathy associated with myasthenia gravis with and without thymic pathology: Report of four cases and literature review. Autoimmun Rev 16: 644–649 (2017).
36. Mathis S, Magy L, Corcia P, Ghorab K, Richard L, Ciron J, Duchesne M, Vallat J-M Simultaneous Combined Myositis, Inflammatory Polyneuropathy, and Overlap Myasthenic Syndrome. Case Rep Neurol Med 2016: 1–11 (2016).
37. Pestronk A, Kos K, Lopate G, Al-Lozi MT Brachio-cervical inflammatory myopathies: Clinical, immune, and myopathologic features. Arthritis Rheum 54: 1687–1696 (2006).
38. Kon T, Mori F, Tanji K, Miki Y, Kimura T, Wakabayashi K Giant cell polymyositis and myocarditis associated with myasthenia gravis and thymoma. Neuropathology 33: 281–287 (2013).
39. Hill EK, King PH, Hughey LC Dermatomyositis and concomitant overlap myasthenic syndrome: A rare presentation. J Am Acad Dermatol 65: e150–e152 (2011).
40. Yoshidome Y, Morimoto S, Tamura N, Kobayashi S, Tsuda H, Hashimoto H, Takasaki Y A case of polymyositis complicated with myasthenic crisis. Clin Rheumatol 26: 1569–1570 (2007).
41. Antoine JC, Camdessanché JP, Absi L, Lassablière F, Féasson L Devic disease and thymoma with anti- central nervous system and antithymus antibodies. Neurology 62: 978–980 (2004).
42. Otton SH, Standen GR, Ormerod IEC T cell lymphocytosis associated with polymyositis, myasthenia gravis and thymoma. Clin Lab Haematol 22: 307–308 (2000).
43. Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, Nagane Y, Maruta T, Satoh T, Sato H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66: 1334–1338 (2009).
44. Gidron A, Quadrini M, Dimov N, Argiris A Malignant thymoma associated with fatal myocarditis and polymyositis in a 32-year-old woman with a history of hairy cell leukemia. Am J Clin Oncol 29: 213– 214 (2006).
45. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N Three Types of Striational Antibodies in Myasthenia Gravis. Autoimmune Dis 2011: 1–7 (2011).
46. Kao JC, Brickshawana A, Liewluck T Neuromuscular Complications of Programmed Cell Death-1 ( PD- 1 ) Inhibitors. Curr Neurol Neurosci Rep 18: 1–9 (2018).
47. Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, Ando Y, Matsukawa M, Inoue H, Kiyotani K, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107: 1055–1058 (2016).
48. Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, Szwebel T-A, Kramkimel N, Lethrosne C, Bruch J-F, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91: e985–e994 (2018).
49. Chen JH, Lee KY, Hu CJ, Chung CC Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review. Med (United States) 96: 1–4 (2017).
50. Tan RYC, Toh CK, Takano A Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis. J Thorac Oncol 12: e90–e91 (2017).
51. Chang E, Sabichi AL, Sada YH Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder. J Immunother 40: 114–116 (2017).
52. Liewluck T, Kao JC, Mauermann ML PD-1 Inhibitor-associated Myopathies : Emerging Immune- mediated Myopathies. J Immunother 41: 208–211 (2018).
53. Chen YH, Liu FC, Hsu CH, Chian CF Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma. Medicine (Baltimore) 96: e7350 (2017).
54. Bourgeois-Vionnet J, Joubert B, Bernard E, Sia MA, Pante V, Fabien N, Honnorat J, Streichenberger N Nivolumab-induced myositis: A case report and a literature review. J Neurol Sci 387: 51–53 (2018).
55. Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, Halfdanarson TR, Wijdicks EF, Goetz MP Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm Pembrolizumab,. Ann Oncol 28: 675 (2017).
56. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu S, Sharma P Acute rhabdomyolysis with severe polymyositis following ipilimumab- nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4: 1–5 (2016).
57. Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V, Franck N, Kramkimel N, Borden A, Touat M, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol 27: 1352–1353 (2016).
58. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375: 1749–1755 (2016).
59. Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, et al. Neurological complications associated with anti–programmed death 1 (PD-1) antibodies. JAMA Neurol 74: 1216–1222 (2017).
60. Fox E, Dabrow M, Ochsner G A Case of Nivolumab-Induced Myositis. Oncologist 21: e3 (2016).
61. Saini L, Chua N Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine. Leuk Lymphoma 58: 2011–2013 (2017).
62. Behling J, Kaes J, Münzel T, Grabbe S, Loquai C New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res 27: 155–158 (2017).
63. Huh SY, Shin SH, Kim MK, Lee SY, Son KH, Shin HY Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer. J Clin Neurol 14: 115–117 (2018).
64. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60: 210–225 (2016).
65. Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment. J Immunother 40: 221–223 (2017).
66. Gandiga PC, Wang AR, Gonzalez-Rivera T, Sreih AG Pembrolizumab-associated inflammatory myopathy. Rheumatol (United Kingdom) 57: 397–398 (2018).
67. Yoshioka M, Kambe N, Yamamoto Y, Suehiro K, Matsue H Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol 42: 1008–1009 (2015).
68. Ogawa T, Ishitsuka Y, Koguchi-Yoshioka H, Tanaka R, Fujisawa Y, Ishii A, Tamaoka A, Fujimoto M Polymyositis induced by PD-1 blockade in a patient in hepatitis B remission. J Neurol Sci 381: 22–24 (2017).
69. Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis (2018).
70. Uchio N, Taira K, Ikenaga C, Unuma A, Kadoya M, Kubota A, Toda T, Shimizu J Granulomatous myositis induced by anti–PD-1 monoclonal antibodies. Neurol Neuroimmunol Neuroinflamm 5: e464 (2018).
71. Bombardieri M, Lewis M, Pitzalis C Ectopic lymphoid neogenesis in rheumatic autoimmune diseases. Nat Rev Rheumatol 13: 141–154 (2017).
72. Pitzalis C, Jones GW, Bombardieri M, Jones SA Ectopic lymphoid-like structures in infection , cancer and autoimmunity. Nat Rev Immunol 14: 447–462 (2014).
73. De Padilla CML, Vallejo AN, Lacomis D, Mcnallan K, Reed AM Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset Juvenile dermatomyositis. Arthritis Rheum 60: 1160–1172 (2009).
74. Radke J, Pehl D, Goebel HH The lymphoid follicle variant of dermatomyositis. Neurol Neuroimmunol Neuroinflammation 1: e19 (2014).
75. Radke J, Koll R, Preuße C, Pehl D, Todorova K, Schönemann C, Allenbach Y, Aronica E, de Visser M, Heppner FL, et al. Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis. Neurol - Neuroimmunol Neuroinflammation 5: e451 (2018).
76. Bleecker JLDE, Engel AG, Butcher EC Peripheral lymphoid tissue-like adhesion molecule expression in nodular infiltrates in inflammatory myopathies. Neuromuscul Disord 6: 255–260 (1996).
77. Rose MR, Ibm E, Group W 188th ENMC international workshop: Inclusion body myositis, 2–4 December 2011, Naarden, the Netherlands. Neuromuscul Disord 23: 1044–1055 (2013).
78. Iannuzzi MC, Rybicki BA, Teirstein AS Sarcoidosis. N Engl J Med 357: 2153–2165 (2007).
79. Maekawa R, Shibuya H, Hideyama T, Shiio Y A case of myasthenia gravis with invasive thymoma associated with diffuse panbronchiolitis, alopecia, dysgeusia, cholangitis and myositis. Clin Neurol 54: 703–708 (2014).
80. Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, Ogawa G, Nagane Y, Kuwana M, Suzuki N Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur J Neurol 21: 223–230 (2014).
81. Iwatsubo T, Arahata K, Motoyoshi Y, Murayama S, Mannen T Co-existence of clinical and immunohistochemical features of polymyositis and myasthenia gravis. Clin Neurol 28: 913–918 (1988).
82. Yamaguchi Y, Sakurai Y, Mannen T, Shimizu J Rapidly progressive polymyositis with elevated antiacetylcholine receptor antibody activity. Intern Med 39: 1108–1110 (2000).
83. Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M, Miwa Y, Yajima N, Maezawa R, Arai S, et al. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study. Neurology 87: 300–308 (2016).
84. Kadoya M, Hida A, Hashimoto Maeda M, Taira K, Ikenaga C, Uchio N, Kubota A, Kaida K, Miwa Y, Kurasawa K, et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol neuroinflammation 3: e290 (2016).
85. Kabasawa C, Shimizu Y, Suzuki S, Masuda M, Nagane Y, Utsugisawa K, Suzuki Y Taste disorders in myasthenia gravis : a multicenter cooperative study. Eur J Neurol 20: 205–207 (2013).
86. Inukai A, Kuru S, Liang Y, Takano A, Kobayashi Y, Sakai M, Doyu M, Sobue G Expression of HLA- DR and its enhancing molecules in muscle fibers in polymyositis. Muscle and Nerve 23: 385–392 (2000).
87. Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y, Suzuki S, Suzuki N, Nishino I Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology 88: 493– 500 (2016).
88. Nakano S, Engel AG Myasthenia gravis: Quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 43: 1167–1172 (1993).
89. Schoser B, Jacob S, Hilton-Jones D, Müller-Felber W, Kubisch C, Claus D, Goebel HH, Vita G, Vincent A, Toscano A, et al. Immune-mediated rippling muscle disease with myasthenia gravis: A report of seven patients with long-term follow-up in two. Neuromuscul Disord 19: 223–228 (2009).
90. George JS, Harikrishnan S, Ali I, Baresi R, Hanemann CO Acquired rippling muscle disease in association with myasthenia gravis. J Neurol Neurosurg Psychiatry 81: 125–126 (2010).
91. Lo HP, Bertini E, Mirabella M, Domazetovska A, Dale RC, Petrini S, D’Amico A, Valente EM, Barresi R, Roberts M, et al. Mosaic caveolin-3 expression in acquired rippling muscle disease without evidence of myasthenia gravis or acetylcholine receptor autoantibodies. Neuromuscul Disord 21: 194–203 (2011).
92. Travis WD, Brambilla E, Müller-hermelink HK, Harris CC (2004) World Health Organization Classification of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon.
93. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB Myasthenia gravis Recommendations for clinical research standards. Neurology 16–23 (2000).
94. Plotz PH, Dalakas M, Richard L, A LL, Miller FW, Mary C Current Concepts in the Idiopathic Inflammatory Myopathies: Polymyositis, Dermatomyositis, and Related Disorders. Ann Intern Med 111: 143–157 (1989).
95. Müller-Hermelink HK, A.Marx Thymoma. Curr Opin Oncol 12: 426–433 (2000).
96. Jordan B, Eger K, Zierz S Thymomassoziierte Polymyositis. Nervenarzt 80: 708–711 (2009).
97. Sasaki H, Yano M, Kawano O, Hikosaka Y, Fujii Y Thymoma associated with fatal myocarditis and polymyositis in a 58-year-old man following treatment with carboplatin and paclitaxel: A case report. Oncol Lett 3: 300–302 (2012).
98. Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 50: 64–72 (2001).
99. Evoli A, Minisci C, Schino C Di, Marsili F, Punzi C, Batocchi AP Thymoma in patients with MG: Characteristics and long-term outcome. Neurology 59: 1844–1850 (2002).
100. Fukuhara M, Higuchi M, Owada Y, Inoue T, Watanabe Y, Yamaura T, Muto S, Hasegawa T, Suzuki H Clinical and pathological aspects of microscopic thymoma with myasthenia gravis and review of published reports. J Thorac Dis 9: 1592–1597 (2017).
101. Vincent A, Willcox N The role of T-Cells in the initiation of autoantibody responses in thymoma patients. Pathol Res Pract 195: 535–540 (1999).
102. van der Meulen MFG, Bronner IM, Hoogendijk JE, Burger H, Venrooij WJ van, Voskuyl AE, Dinant HJ, Linssen WHJP, Wokke JHJ Polymyositis: An overdiagnosed entity. Neurology 61: 316–321 (2003).
103. Vilela VS, Prieto-González S, Milisenda JC, Selva-O´Callaghan A, Grau JM Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up. Rheumatol Int 35: 915–920 (2015).
104. Le Roux K, Streichenberger N, Vial C, Petiot P, Feasson L, Bouhour F, Ninet J, Lachenal F, Broussolle C, Sève P Granulomatous myositis: A clinical study of thirteen cases. Muscle and Nerve 35: 171–177 (2007).
105. NEUROMUSCULAR DISEASE CENTER: BRACHIO-CERVICAL INFLAMMATORY MYOPATHY (https://neuromuscular.wustl.edu/pathol/bcim.htm).
106. Shelly S, Agmon-levin N, Altman A, Shoenfeld Y Thymoma and autoimmunity. Cell Mol Immunol 8: 199–202 (2011).
107. Liewluck T Immune-Mediated Rippling Muscle Disease: Another Inflammatory Myopathy in Myasthenia Gravis. Arch Neurol 67: 896–897 (2010).
108. Skeie GO, Romi F, A.Aarli J, Pal TB, Gilhus NE Pathogenesis of Myositis and Myasthenia Associated with Titin and Ryanodine Receptor Antibodies. Ann NY Acad Sci 998: 343–350 (2003).
109. Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1–8 (2017).
110. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci 102: 11823–11828 (2005).
111. Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, Hiai H, Honjo T, Okazaki T PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol 22: 443–452 (2010).
112. Wiendl H, Mitsdoerffer M, Schneider D, Chen L, Lochmüller H, Melms A, Weller M Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J 17: 1892–1894 (2003).
113. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8: 239–245 (2007).
114. Okazaki T, Honjo T PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 19: 813–824 (2007).
115. Chuang WY, Scröbel P, Gold R, Nix W, Schalke B, Kiefer R, Opitz A, Klinker E, Müller-Hermelink HK, Marx A A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 58: 644–648 (2005).
116. Matsumoto K, Miyake Y, Matsushita H, Ohnishi A, Ikeda F, Hidenori S, Akinobu T, Nouso K, Yamamoto K Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. J Gastroenterol Hepatol 29: 110–115 (2014).
117. Miro O, Pedrol E, Casademont J, Garcia-Carrasco M, Sanmarti R, Cebrian M, Grau JM Muscle involvement in rheumatoid arthritis:Clinicopathological study of 21 symptomatic cases. Semin Arthritis Rheum 25: 421–428 (1996).
118. Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, Kobashi Y, Kubo T, Aihara K, Chin K, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med 105: 1238–1247 (2011).
119. Highton J, Hung N, Hessian P, Wilsher M Pulmonary rheumatoid nodules demonstrating features usually associated with rheumatoid synovial membrane. Rheumatology 46: 811–814 (2007).
120. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F Meningeal B- cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089–1104 (2007).